Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FOLFIRINOX study in resectable or borderline resectable pancreatic adenocarcinoma
jRCT1041220027Phase 2Active, not recruiting
- Start
- Jul 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, folinic acid, irinotecan and fluorouracil in pancreatic adenocarcinoma (PDAC) and pancreatic adenosquamous carcinoma (PASC) (2 arms). Primary endpoint: R0 resection rate. Started Jul 2022; status: active, not recruiting.
02
Drugs
oxaliplatinfolinic acidirinotecanfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on jRCT1041220027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041220027.